MedTrace Logo

Replexa+ Shortwave Diathermy Device for Patients Diagnosed With Peripheral Artery Disease and Peripheral Neuropathy

NCT07336381 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-01-15

No results posted yet for this study

Summary

This research project is designed to see if treatment with the Replexa+ shortwave diathermy device daily for 3 months will improve blood flow in the lower legs and feet of patients diagnosed with peripheral artery disease and peripheral neuropathy.

Conditions

Interventions

DEVICE

Replexa shortwave diathermy

Treatment with home use of the Replexa+ shortwave diathermy device twice daily for 3 months.

Sponsors & Collaborators

  • ProMedTek, Inc.

    collaborator UNKNOWN

  • Indiana University

    lead OTHER

Principal Investigators

  • Michael P. Murphy, MD · VA Medical Center, Indiana University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-05
Primary Completion
2026-12-31
Completion
2026-12-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07336381 on ClinicalTrials.gov